



NAVANA PHARMA

NAVANA PHARMACEUTICALS LIMITED

Corporate Office: House # 99, Road # 04, Block # B, Banani, Dhaka-1213

PRICE SENSITIVE INFORMATION

This is for kind information to all valued shareholders of Navana Pharmaceuticals Limited and stakeholders that the Board of Directors of the company in its 24th meeting held on 13th April, 2023 ended at 3.00 p.m. has considered and approved, among others, the Un-audited Financial Statements for the Third quarter (Q3) period ended on March 31, 2023 and took the following Price Sensitive Decision:-

Comparative Statement on Un-audited Financial Statement for the Third quarter (Q3, FY-2022-2023) period ended on March 31, 2023

| Sl. No | Particulars | 01.07.2022-31.03.2023 | 01.07.2021-31.03.2022 | 01.01.2023-31.03.2023 | 01.01.2022-31.03.2022 |
|--------|---|-------------------------|-------------------------|-----------------------|-----------------------|
| I | Earnings Per Share (EPS) | 2.57 | 2.39 | 1.09 | 0.85 |
| II | Net Operating Cash Flow Per Share(NOCFPS) | 2.85 | 2.13 | N/A | N/A |
| | | As at 31.03.2023 | As at 30.06.2022 | | |
| III | Net Asset Value (NAV) | 4,393,453,670 | 3,483,049,324 | N/A | N/A |
| IV | Net Asset Value Per Share | 40.90 | 43.41 | N/A | N/A |

Notes:*** Reasons of significant deviation in earning per share (EPS) and Net Operating Cash Flows Per share (NOCFPS) between the quarterly periods:**

* EPS: Increase in 16% Sales Revenue and efficient usages of material resulted in increased gross profit for the reporting period. The reduced corporate tax rate for the period resulted in the increment of Earnings per Share as well.

* NOCFPS: The growth in business volume and efficient utilization of working capital resulted in increased NOCFPS.

* In compliance with the Dhaka & Chittagong Stock Exchange (Listing) Regulation, 2015, the company is pleased to publish the Un-audited Financial Statement for the third quarter (Q3) period ended on March 31, 2023 in two widely circulated daily newspapers (one in Bengali and other one in English) and also in an online news portal. The detail of the published quarterly Financial Statements will be available in the website (www.navanapharma.com) of the company.

Dated: April 13, 2023

By order of the Board
Sd/-**Joynul Abedin ACS**
Company Secretary